The effect of daily low-dose aspirin versus placebo on the progression of age-related hearing loss in healthy older adults.
What to know about Alnylam’s upcoming readout on its heart drug
Next week, the biopharma world will see eagerly awaited results from a trial that could shape care for patients with an increasingly common heart condition